Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

17-11-2020 | Heart failure | Commentary

17-11-2020 | Heart failure | Commentary

Takeaways from the SCORED and SOLOIST-WHF trials

Deepak Bhatt discusses the performance of sotagliflozin in trials focusing on acute heart failure and on chronic kidney disease (11:56).

Related content

17-11-2020 | Sotagliflozin | News

SOLOIST-WHF: Sotagliflozin beneficial when started shortly after acute heart failure episode

17-11-2020 | Sotagliflozin | Highlight | News

​​​​​​​Sotagliflozin SCORED cardiovascular risk reduction in people with type 2 diabetes, CKD

14-06-2020 | ADA 2020 | Conference coverage | News

Canagliflozin reduces risk for first, total HF events in type 2 diabetes with CKD

01-09-2020 | Dapagliflozin | News

DAPA-CKD shows dapagliflozin benefits regardless of diabetes
Image Credits